Baltimore-Washington Financial Advisors’s Myriad Genetics MYGN Stock Holding History

Baltimore-Washington Financial Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-6,330	Closed	-$215K	–	292
2015 Q2	$215K	Sell	6,330 -42,265	-87%	-$1.44M	0.06%	92
2015 Q1	$1.72M	Buy	+48,595	New	+$1.74M	0.5%	70
2014 Q1	–	Sell	-46	Closed	-$1K	–	268
2013 Q4	$1K	Buy	+46	New	+$1.16K	﹤0.01%	288

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baltimore-Washington Financial Advisors's MYGN Position: Q3 2015 in Review

Baltimore-Washington Financial Advisors sold out of Myriad Genetics (MYGN) in Q3 2015, closing a stake of 6,330 shares — an estimated $215K sold.

Baltimore-Washington Financial Advisors first reported a position in MYGN in Q4 2013 and held it in 3 quarters. The position peaked at $1.72M in Q1 2015. 234 funds tracked by Wall St. Rank hold MYGN as of Q3 2015.

Baltimore-Washington Financial Advisors reported no remaining Myriad Genetics position as of Q3 2015 after selling out during the quarter.
Baltimore-Washington Financial Advisors sold 6,330 Myriad Genetics shares in Q3 2015, an estimated $215K.
Baltimore-Washington Financial Advisors first reported a position in Myriad Genetics in Q4 2013 and held it in 3 quarters.
Baltimore-Washington Financial Advisors's Myriad Genetics position peaked at $1.72M in Q1 2015.
234 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2015.

Based on Baltimore-Washington Financial Advisors's 13F filing for Q3 2015, filed 16 Oct 2015.